75 min listen
Inhibitors: Prevention, Eradication, and Lived Experiences
Inhibitors: Prevention, Eradication, and Lived Experiences
ratings:
Length:
41 minutes
Released:
Feb 10, 2022
Format:
Podcast episode
Description
Inhibitor development has long been considered the most significant complication of severe hemophilia, but with the licensure of the first non-factor therapy and a robust pipeline of novel and gene therapeutics being investigated, is it still of critical importance that we better understand inhibitors? If so, what research is currently taking place, and what can he hope to learn from it? This episode of the Global Hemophilia Report from BloodStream Media features contributions and citations from investigators, clinicians, and research funders dedicated to this topic, as well as from patients and caregivers who can speak to their lived experience of inhibitors. For more on inhibitor research: Inhibitors and Hemophilia - CDC ATHN 8: PUPs Matter Study - ATHN The Hemophilia Inhibitor Eradication Trial - ClinicalTrials.gov A New Plan for Tackling Inhibitors - NHF ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders - ASH The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development - ASH Show Notes: Featured Advertiser: Sanofi Genzyme Subscribe to BloodStream Media’s Global Hemophilia Report Senior Adviser: Dr. Donna DiMichele Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook BloodStream on Twitter
Released:
Feb 10, 2022
Format:
Podcast episode
Titles in the series (31)
Mid-Point Conversations: A Summary: On this episode, Executive Producer of the , Patrick James Lynch, is joined in person by Senior Advisor, Dr. Donna DiMichele, and Writer/Host, Laurence Woollard, to reflect on Season 1 so far as well as debate existing and emerging research priorities... by Global Hemophilia Report